Published in AIDS Weekly, October 15th, 2001
"Licensing our first new chemical entity represents a new step forward for Atrix," said David R. Bethune, chairman and chief executive officer at Atrix. "Our goal is to deliver a unique, physiologically relevant growth promoting compound using our Atrigel drug delivery technology. With a recently developed sustained-release formulation, we believe we will be able to capitalize on this opportunity and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.